Parkinson Disease Psychosis Clinical Trial
Official title:
A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis
This study will be conducted as a 16-week, multi-center, single-arm, open-label study. Pimavanserin will be administered at a dose of 34 mg to approximately 50 subjects with PDP ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05824728 -
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
|
Phase 2 | |
| Terminated |
NCT03152292 -
The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
|
||
| Withdrawn |
NCT05344365 -
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
|
Phase 2 | |
| Recruiting |
NCT05357612 -
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
|
Phase 4 | |
| Completed |
NCT02969369 -
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
|
Phase 2 | |
| Not yet recruiting |
NCT05995782 -
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
|
Phase 1 | |
| Recruiting |
NCT04579887 -
Presence Hallucination in Parkinson's Disease
|
N/A | |
| Recruiting |
NCT04592965 -
Hallucinations in Parkinson's Disease
|
N/A | |
| Completed |
NCT05240339 -
Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
|
||
| Recruiting |
NCT03661125 -
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
|
Early Phase 1 |